Clinical trial
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated…
NCT00051974 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00051974 |
|---|---|
| Title | Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer |
| Official title | A Randomized, Multicenter, Open-Label, Phase 2 Study of VELCADE Alone or VELCADE Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | VELCADE™ (bortezomib) for Injection (formerly PS-341) |
| Enrollment | 155 |
| Start date | Dec 1, 2002 |
| Primary completion | Sep 1, 2004 |
| First posted | Jan 22, 2003 |
| Last update posted | Feb 11, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: